rosiglitazone has been researched along with Cardiomyopathies, Primary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou Daya, K; Abu Daya, H; Nahhas, G; Nasser Eddine, M; Nuwayri-Salti, N | 1 |
| Califf, RM; Kramer, JM | 1 |
| Baek, SH; Chang, K; Ihm, SH; Kim, HY; Kim, JH; Seung, KB; Youn, HJ | 1 |
| AbdelGawad, H; Baraka, A | 1 |
| Fowler, MB; Gambhir, SS; Kao, DP; Quon, A; Witteles, RM; Wu, JC | 1 |
| Bhandari, S; Semple, DJ; Seymour, AM | 1 |
| Lu, YL; Wang, NC; Wang, XF; Wang, YN; Wu, H; Yu, DL; Zhang, L; Zhao, JB; Zhu, L | 1 |
7 other study(ies) available for rosiglitazone and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ).
Topics: Animals; Body Weight; Cardiomyopathies; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Insulin; Male; Myocardium; Myocytes, Cardiac; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2015 |
The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Topics: Cardiomyopathies; Diabetes Mellitus, Type 2; Drug Approval; Gene Expression Regulation; Humans; Hypoglycemic Agents; National Institutes of Health (U.S.); Product Surveillance, Postmarketing; Public Policy; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2008 |
Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Topics: Animals; Body Weight; Cardiomyopathies; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Fibrosis; Glucose Tolerance Test; Male; Myocardium; PPAR gamma; Rats; Rats, Inbred OLETF; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones | 2010 |
Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
Topics: Animals; Apoptosis; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Fenofibrate; Hypertrophy, Left Ventricular; Hypolipidemic Agents; Male; Myocytes, Cardiac; Oxidative Stress; PPAR alpha; PPAR gamma; Rats; Rosiglitazone; Streptozocin; Thiazolidinediones | 2010 |
Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy.
Topics: Animals; Cardiomyopathies; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardium; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2010 |
Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Uremia | 2012 |
[Protective effect of rosiglitazone on myocardium in diabetic cardiomyopathy of rats].
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Ligands; Male; Myocardium; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2006 |